Header

UZH-Logo

Maintenance Infos

KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective


Blank, P R; Moch, H; Szucs, T D; Schwenkglenks, M (2011). KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clinical Cancer Research, 17(19):6338-6346.

Abstract

PURPOSE: Monoclonal antibodies against the epidermal growth factor receptor (EGFR), such as cetuximab, have led to significant clinical benefits for metastatic colorectal cancer (mCRC) patients but have also increased treatment costs considerably. Recent evidence associates KRAS and BRAF mutations with resistance to EGFR antibodies. We assessed the cost-effectiveness of predictive testing for KRAS and BRAF mutations, prior to cetuximab treatment of chemorefractory mCRC patients. EXPERIMENTAL DESIGN: A life-long Markov simulation model was used to estimate direct medical costs (€) and clinical effectiveness (quality adjusted life years, QALYs) of the following strategies: KRAS testing, KRAS testing with subsequent BRAF testing of KRAS-wildtypes (KRAS/BRAF), cetuximab treatment without testing. Comparison was against no cetuximab treatment (reference strategy). In the testing strategies, cetuximab treatment was initiated if no mutations were detected. Best supportive care was given to all patients. Survival times/utilities were derived from published randomised clinical trials. Costs were assessed from the perspective of the Swiss health system.RESULTS: Average remaining life-time costs ranged from €3'983 (no cetuximab) to €38'662 (no testing). Cetuximab treatment guided by KRAS/BRAF achieved gains of 0.491 QALYs compared to the reference strategy. The KRAS testing strategy achieved an additional gain of 0.002 QALYs compared to KRAS/BRAF. KRAS/BRAF testing was the most cost-effective approach when compared to the reference strategy (incremental cost-effectiveness ratio: €62'653/QALY). CONCLUSION: New predictive tests for KRAS and BRAF-status are currently being introduced in pathology. Despite substantial costs of predictive testing, it is economically favourable to identify patients with KRAS and BRAF wildtype status.

Abstract

PURPOSE: Monoclonal antibodies against the epidermal growth factor receptor (EGFR), such as cetuximab, have led to significant clinical benefits for metastatic colorectal cancer (mCRC) patients but have also increased treatment costs considerably. Recent evidence associates KRAS and BRAF mutations with resistance to EGFR antibodies. We assessed the cost-effectiveness of predictive testing for KRAS and BRAF mutations, prior to cetuximab treatment of chemorefractory mCRC patients. EXPERIMENTAL DESIGN: A life-long Markov simulation model was used to estimate direct medical costs (€) and clinical effectiveness (quality adjusted life years, QALYs) of the following strategies: KRAS testing, KRAS testing with subsequent BRAF testing of KRAS-wildtypes (KRAS/BRAF), cetuximab treatment without testing. Comparison was against no cetuximab treatment (reference strategy). In the testing strategies, cetuximab treatment was initiated if no mutations were detected. Best supportive care was given to all patients. Survival times/utilities were derived from published randomised clinical trials. Costs were assessed from the perspective of the Swiss health system.RESULTS: Average remaining life-time costs ranged from €3'983 (no cetuximab) to €38'662 (no testing). Cetuximab treatment guided by KRAS/BRAF achieved gains of 0.491 QALYs compared to the reference strategy. The KRAS testing strategy achieved an additional gain of 0.002 QALYs compared to KRAS/BRAF. KRAS/BRAF testing was the most cost-effective approach when compared to the reference strategy (incremental cost-effectiveness ratio: €62'653/QALY). CONCLUSION: New predictive tests for KRAS and BRAF-status are currently being introduced in pathology. Despite substantial costs of predictive testing, it is economically favourable to identify patients with KRAS and BRAF wildtype status.

Statistics

Citations

41 citations in Web of Science®
44 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

152 downloads since deposited on 15 Sep 2011
19 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Pathology and Molecular Pathology
04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2011
Deposited On:15 Sep 2011 09:03
Last Modified:05 Apr 2016 15:00
Publisher:American Association for Cancer Research
ISSN:1078-0432
Publisher DOI:https://doi.org/10.1158/1078-0432.CCR-10-2267
PubMed ID:21807639

Download

Preview Icon on Download
Preview
Content: Accepted Version
Filetype: PDF
Size: 2MB
View at publisher